Background. Based on review of patient data in case conferences over time, we hypothesized that clinically relevant data are omitted in routine soft tissue sarcoma staging. Methods. We examined subsets of a prospectively collected single institution soft tissue sarcoma database with respect to criteria of the AJCC versions 6 (2002) and 7 (2010) staging systems and examined their clinical outcomes.
ABSTRACT
Background. Based on review of patient data in case conferences over time, we hypothesized that clinically relevant data are omitted in routine soft tissue sarcoma staging. Methods. We examined subsets of a prospectively collected single institution soft tissue sarcoma database with respect to criteria of the AJCC versions 6 (2002) and 7 (2010) staging systems and examined their clinical outcomes.
Results. Relapse-free survival decreases with increasing primary tumor size in four categories, versus two categories used in AJCC 6 and 7 staging. Disease-specific survival decreases over three categories. Conversely, omission of tumor depth as a prognostic factor in version 7 appears supported, since tumor depth is not an independent risk factor for disease-specific survival by multivariate analysis. Patients with nodal disease and no other metastases fare better than patients with other metastases, but have inferior outcomes compared with patients with large high-grade tumors without nodal metastasis. Multivariate analysis identified size, site, grade, age, nodal metastatic disease, and other metastatic disease as independent risk factors for disease-specific survival. Versions 6 and 7 criteria are tacit regarding anatomic site and histology for tumors with identical FNCLCC grade. Conclusions. Improved patient risk assessment may be achieved by staging using a larger number of size categories. Staging system refinements come at the cost of a larger number of staging categories. Histology or sitespecific staging systems, nomograms or Bayesian belief networks may provide more accurate means to assess clinical outcomes.
Clinical staging of cancer is fundamentally important when discussing patient outcomes. It is now possible to predict accurately the risk of cancer recurrence and mortality and thus to adapt therapy according to risk. 1 Prognostic factors for outcome vary based on the endpoint, be it local recurrence, disease-specific survival, overall survival, or distant disease-free survival. 2 Tumor size, nodal status, and presence or absence of metastatic disease (TNM systems) have been used most frequently to assess risk and to stage patients. For soft tissue sarcomas, tumor grade is an important prognostic factor. Other factors, such as serum tumor markers, are part of staging systems for only a minority of cancers, e.g., testicular cancer. Tumor genetics are observed to impact clinical outcomes for patients with hematological malignancies and solid tumors, e.g., non-small cell lung adenocarcinoma and sarcomas such as gastrointestinal stromal tumors and rhabdomyosarcoma, and are debated in synovial sarcoma, but are presently not routinely used in soft tissue sarcoma staging. [3] [4] [5] [6] [7] [8] [9] [10] Substantial efforts have been made to accurately grade and stage soft tissue sarcomas (STS). [11] [12] [13] [14] [15] [16] STS staging is hampered by its low incidence (\1 % of all human cancers with more than 50 histological subtypes) and the use of varied systems for grade and stage. The Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system of tumor grading better predicted outcome compared with a National Institutes of Health (NIH) staging system.
14 Also, 2-, 3-, and 4-grade systems have been used to grade tumors, further complicating staging system comparisons.
The American Joint Committee on Cancer (AJCC) Cancer Staging Handbook, 7th edition was released in 2010 and updated the 6th edition adopted in 2002. 17, 18 In the newest staging system, the FNCLCC system was adopted for tumor grading, eliminating the issue of 2-versus 3-versus 4-grade systems of STS grading of version 6. 13 The depth of tumor is recorded in the 7th edition as in the 6th, but now does not impact tumor stage. Patients with draining node involvement are now included as stage III, a change from stage IV in version 6.
In reviewing the changes between AJCC versions 6 and 7, we could not identify supporting data to suggest the changes made, save for a publication demonstrating that N1M0 patients fare better than N1M1 patients and concluded that such N1M0 patients had overall survival similar to AJCC version 6 G3T2N0 patients. 19 Conversely, data were presented between the publication of AJCC versions 6 and 7 that suggest that other changes in the staging system should be effected. In one study, the risk of tumor recurrence increased as primary size increased more than 10 cm, which had been addressed in neither version 6 nor 7.
15 STS are not presently staged based on anatomic primary site, even though primary site has an impact on outcome. 12 Finally, version 7 functionally eliminated the use of superficial versus deep primary site, a known prognostic factor for recurrence of extremity sarcomas. 12, 15 Histology is also an important prognostic factor, as highlighted by the new GIST staging system in version 7.
Based on the data above, as well as our own experience in weekly staging meetings, we hypothesized that outcomes from STS categorization by AJCC versions 6 and 7 did not accurately reflect patient outcomes. We investigated the impact of clinical variables on patient outcome using a prospectively collected single-institution STS database.
METHODS
Between July 1, 1982, and June 30, 2010, 8647 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC) were identified from an institutional review board (IRB)-approved prospective STS database. Clinicopathologic data included age at diagnosis, sex, histologic type, tumor depth, grade, site, size, margin status, nodal status, presence of other metastatic disease, indication for radiotherapy (RT), radiation dose, and use of concomitant chemotherapy. Tumor depth and grade were defined as previously reported. 20 Of note, the MSKCC database has not been coded by FNCLCC grade, and it is only possible in our analyses of grade to comment on low-and highgrade tumors (tumors classified as stage I and III in both versions 6 and 7) and not on intermediate grade tumors per se. Those tumors termed grade 2 (G2) on a 3-grade scale are combined with G3 tumors, consistent with AJCC version 6. Sites of disease were defined as (1) extremity (upper and lower extremity), (2) abdomen or retroperitoneum (abdomen/RP), and (3) trunk (chest wall, proximal extremity/groin, thoracic, head and neck). Tumor size was recorded as the largest dimension and was also stratified as B5, [5-10, [10-15 , and [15 cm. Margins of resection were defined as R0 (negative), R1 (microscopically positive), and R2 (grossly positive).
The primary end point of the analysis was disease-specific survival (DSS), defined as time from date of surgery to date of death as a result of disease or treatment complication. Recurrence-free survival (RFS) was a secondary endpoint, defined as the date of surgery to the date of the event indicating disease recurrence. The influence of clinicopathologic features on DSS and RFS was analyzed using the Kaplan-Meier method and the log-rank test in the univariate setting and using a Cox proportional hazard regression analysis in the multivariate setting. A p value \0.05 was considered significant.
RESULTS

Patient Outcome by Tumor Size
In AJCC versions 6 and 7, primary STS are segregated into sizes B5 or [5 cm. From this database, the risk of local recurrence increases with primary tumor size and continues to increase from B5 to [5-10, [10-15, and [15 cm primary tumors. With the use of 4 size classes, local recurrence-free survival (LRFS) (Fig. 1a) RFS (Fig. 1b) demonstrated a statistically significant decline with each size category. Disease-specific survival (DSS) also declined as primary tumor size increased, but was similar in the [10-15 and [15 cm categories (Fig. 1c) , p = 0.91 for the comparison of [10-15 and [15 cm categories. Similar statistically significant differences in LRFS, RFS, and DSS are observed using 3 tumor size categories, B5, [5-10, and [10 cm (data not shown).
Patient Outcome by Tumor Depth
In prior analyses, tumor depth was shown to be a clinically important variable for patient outcomes. 11, 12, 15, 21 By including STS with a primary site of extremity, trunk, and head/neck and specifically omitting intra-abdominal, retroperitoneal, and visceral primaries, where there are no superficial STS, depth remains a statistically significant predictor of local RFS (Fig. 2a) , overall RFS (Fig. 2b) , and DSS ( Fig. 2c ) (log rank, p \ 0.001 in each case). Similar outcomes are observed examining only extremity and trunk primary sites (data not shown).
In a Cox proportional hazards multivariate analysis including anatomic site and 4 size categories (Table 1) , statistically significant factors predicting DSS include patient age above or below the median (54.4 years), primary tumor size, primary site, and grade, but not gender. Primary tumor depth is not an independent variable predicting overall survival. This finding is explained at least in part by the relative dearth of large superficial and of smaller deep sarcomas (Fig. 3) .
Patient Outcome by Nodal Status and Other Metastatic Disease
In AJCC version 6, node positive (N1) disease was combined with M1 disease as stage IV. Published series indicated that patients with node positive, metastasis negative (N1M0) disease may fare better than those with any node status, metastasis positive (NXM1) disease, such that N1M0 STS were recoded as stage III in AJCC version 7. 15, 19, 21, 22 In examining this prospectively collected database, patients with any grade, any tumor size, node positive, metastasis negative (GXTXN1M0) disease demonstrated inferior DSS compared with people with other stage III tumors, i.e., grade 3, large primary, node negative, metastasis negative (G3T2N0M0) primary STS, but had superior survival compared with those with N0M1 or N1M1 disease (p \ 0.001, Fig. 4a) .
Thus, the small proportion of patients with N1M0 disease have a DSS intermediate to those with localized disease and overt metastatic disease, with the implication that they represent a unique class of patient for staging purposes, inferior to G3T2 (N0M0) primaries but superior to patients with overt M1 disease. This is borne out in the multivariate analysis, in which nodal disease is significantly worse than no metastatic disease, and N0M1 metastatic disease is significantly worse than N1M0 disease ( with dedifferentiated liposarcoma of the extremity have superior overall survival than those with pleomorphic sarcoma, even though both are G3 by FNCLCC (Fig. 4b) .
DISCUSSION
The present data argue for greater use of histology-or site-specific staging systems, nomograms, and Bayesian belief networks to more accurately assess patient risk than is currently feasible with AJCC staging. The development of cancer staging is an evolving process that attempts to account for both clinical and other variables in determining patient outcome, while at the same time retaining portability. The more accurate assessment of risk, as noted in this and other work since the publication of AJCC version 6, will hopefully allow for a clearer discussion with patients regarding treatment options. While there may not be as much impact in the choice of adjuvant radiation, in which the use of radiation for primaries larger than 5 cm is for most circumstances a standard of care, the choice to use adjuvant chemotherapy, which benefits patients modestly if at all, depending on the clinical situation, may be more greatly affected by the quantitation of increased metastatic risk inherent in larger sarcomas.
Refinements included in AJCC version 7 should help improve staging, in particular, the consistent use of a b c
FIG. 2 a
Local relapse-free survival (time from primary surgery to first local relapse, trunk/extremity/head-neck primary sites only). n = 3,419, excludes six patients with unknown size categories; log rank, p \ 0.001. b Relapse-free survival (time from primary surgery to first local or distant relapse, trunk/extremity/head-neck primary sites only). n = 3,419, excludes six patients with unknown size categories; log rank, p \ 0.001. c Disease-specific survival (time from primary surgery to death from disease, trunk/extremity/headneck primary sites only). n = 3,419, excludes six patients with unknown size categories; log rank, p \ 0.005 Issues that arise from the updating of the AJCC criteria to include FNCLCC grading may merit more thorough study. For example, the terminology for sarcoma subtypes continues to evolve since the 1996 FNCLCC criteria were developed, and newer subtypes have not been assigned differentiation scores. 13 Malignant fibrous histiocytoma (MFH) is now termed high-grade undifferentiated pleomorphic sarcoma (UPS). 23 New entities included in AJCC version 7 (''deep'' angiosarcoma, dermatofibrosarcoma protuberans [DFSP]) are not included in the list of tumor differentiation score, but arguably should be 3 and 1, respectively. Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma are subtypes in AJCC version 7 that have no differentiation grade (grade 2 is suggested). The 2013 update of with the World Health Organization (WHO) soft tissue sarcoma subtypes remains tacit on this, the FNCLCC grade of these tumors. 23 Another issue complicating staging is that the mitotic rate that defines FNCLCC high grade varies by histology. For example, myxoid-round cell liposarcoma is considered high grade if [5 % of the tumor has round cell features, which is not the case for other sarcomas. 24 AJCC version 7 eliminated depth as a variable for outcome and included only 2 size categories for the primary 
FIG. 4 a
Disease-specific survival comparing G3T2N0M0 primary STS to GXTXN1M0 and GXTXN1M1 STS, n = 1440 total; G3T2 N0M0 disease (n = 1123), GXTXN1M0 (n = 33), GXTXN1M1 (n = 15), and GXTXN0M1 disease (n = 269); log rank, p \ 0.001. Comparing GXTXN0M1 and GXTXN1M1 patients; log rank, p = 0.944. 95 % confidence intervals are noted at 5 years for the two largest groups; they are not meaningful for the smallest groups with so few events. b Disease-specific survival comparing extremity dedifferentiated liposarcoma (n = 28) and undifferentiated pleomorphic sarcoma (n = 329); log rank, p \ 0.001 tumor, the latter of which is also the case for version 6. Interestingly, in a prior critique of AJCC 6, primary tumor size did not predict outcome when only retroperitoneal tumors were involved. 25 The lack of large superficial and small deep tumors also argues that retroperitoneal sarcomas should be staged separately. 11, 26 Data provided in this study and other analyses imply the lack of independence of depth as a variable predicting clinical outcomes. 27 This issue may best be examined in a dataset in which FNCLCC grade is homogeneously used, a weakness of our analysis, which examined only high-grade versus low-grade sarcomas. That being said, a number of low-grade sarcoma would be reclassified in FNCLCC terms as intermediategrade, and the differences between low-grade and highgrade STS in that situation is likely to be more pronounced than the data presented here.
As a single-institution study that confirms and extends other work, we also cannot claim that alternative means for staging sarcomas will be superior to AJCC versions 6 or 7. However, even using the now decade-old nomogram for soft tissue sarcoma estimates risks for recurrence or death within ±8 %, a claim that cannot be made with presently available AJCC staging. 12 For example, the quoted AJCC 5-year overall survival data by stage do not include confidence intervals and are based on data published with a previous AJCC staging system without recharacterization of tumors using new criteria. 17 We anticipate refinements to staging systems will allow for more accurate assessments of risk over time, as has now happened for rhabdomyosarcoma (an important sarcoma subtype as pertains to lymph node metastases) and GIST. 8, [28] [29] [30] While these issues are addressed, we suggest that the use of general or anatomic site specific nomograms for soft tissue sarcomas (e.g., www.mskcc.org/nomograms), or staging system for specific anatomic sites or subtypes when feasible. 12, 26, 31, 32 These newer methods allow integration of multiple variables into risk assessment with greatest facility, as may Bayesian strategies for risk classification in the future. 27 While efforts for accurate clinical staging may be swept aside someday through the greater use of the molecular classification of sarcomas, for the time being it remains necessary to use clinical variables to inform treatment decisions. 33 ACKNOWLEDGMENT The Research was support by NCI grants CA47179, CA140146, and CA142860.
